Amylyx (AMLX) CMO executes automatic 6,461-share sale for tax withholding

Rhea-AI Filing Summary

Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian reported an automatic sale of 6,461 shares of common stock on March 2, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were sold at a weighted average price of $14.5806 per share in multiple trades between $14.440 and $14.945. After these tax-related sales, Bedrosian held 169,295 shares of Amylyx common stock directly.

Insider Trade Summary

Net Seller: 6,461 shares ($94,205)

Net Sell 1 txn

Insider Bedrosian Camille L

Role Chief Medical Officer

Sold 6,461 shs ($94K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,461	$14.5806	$94K

Holdings After Transaction: Common Stock — 169,295 shares (Direct)

Footnotes (1)

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.440 to $14.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bedrosian Camille L

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		6,461(1)	D	$14.5806(2)	169,295	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.440 to $14.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen, as Attorney in Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amylyx Pharmaceuticals (AMLX) report for Camille L. Bedrosian?

Amylyx Pharmaceuticals reported that Chief Medical Officer Camille L. Bedrosian sold 6,461 shares of common stock on March 2, 2026. The sale was to cover tax withholding obligations triggered by the vesting of restricted stock units, according to the filing’s footnote disclosure.

Why did Amylyx CMO Camille Bedrosian sell 6,461 AMLX shares?

The 6,461 Amylyx shares were sold automatically to satisfy tax withholding obligations from vesting restricted stock units. The filing states these sales were required and not at Bedrosian’s discretion, indicating the transaction was driven by tax compliance rather than an elective portfolio decision.

What price did Camille Bedrosian receive for the sold Amylyx (AMLX) shares?

The weighted average price for the 6,461 sold Amylyx shares was $14.5806 per share. A footnote explains the shares were sold in multiple transactions, with individual sale prices ranging from $14.440 to $14.945, and detailed trade breakdowns are available to SEC staff upon request.

How many Amylyx Pharmaceuticals shares does Camille Bedrosian own after the reported sale?

Following the tax-withholding sale, Camille Bedrosian directly owned 169,295 shares of Amylyx common stock. This post-transaction balance reflects her remaining equity position after the automatic disposition of 6,461 shares related to the vesting of restricted stock units described in the Form 4 filing.

Was Camille Bedrosian’s sale of Amylyx (AMLX) shares discretionary?

The filing states the sale was not discretionary. Shares were required to be sold to cover tax withholding obligations connected to restricted stock unit vesting, and the footnote clarifies these sales were automatic and not executed at the personal discretion of Camille Bedrosian.